期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma 被引量:4
1
作者 Sabrina C Wentz Zhi-Guo Zhao +5 位作者 Yu Shyr Chan-Juan Shi kay washington Nipun B Merchant Fen Xia A Bapsi Chakravarthy 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2012年第10期207-215,共9页
AIM:Clinicopathologic factors predicting overall survival (OS) would help identify a subset to benefit from adjuvant therapy. METHODS: One hundred and sixty-nine patients patients from 1984 to 2009 with curative resec... AIM:Clinicopathologic factors predicting overall survival (OS) would help identify a subset to benefit from adjuvant therapy. METHODS: One hundred and sixty-nine patients patients from 1984 to 2009 with curative resections for pancreatic adenocarcinoma were included. Tumors were staged by American Joint Committee on Cancer 7th edition criteria. Univariate and multivariable analyses were performed using Kaplan-Meier methodology or Cox proportional hazard models. Log-rank tests were performed. Statistical inferences were assessed by two-sided 5% significance level. RESULTS: Median age was 67.1 (57.2-73.0) years with equal gender distribution. Tumors were in the head (89.3%) or body/tail (10.7%). On univariate analysis, adjuvant therapy, lymph node (LN) ratio, histologic grade, negative margin status, absence of peripancreatic extension, and T stage were associated with improved OS. Adjuvant therapy, LN ratio, histologic grade, number of nodes examined, negative LN status, and absence of peripancreatic extension were associated with improved recurrence-free survival (RFS). On multivariable analysis, LN ratio and carbohydrate antigen (CA) 19-9 levels were associated with OS. LN ratio was associated with RFS. CONCLUSION: The LN ratio and CA 19-9 levels are independent prognostic factors following curative resections of pancreatic cancer. 展开更多
关键词 Pancreatic ADENOCARCINOMA LYMPH node ratio CARBOHYDRATE ANTIGEN 19-9 Recurrence-free SURVIVAL Overall SURVIVAL
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部